Ibrutinib, zanubrutinib, and acalabrutinib are synthetic BTK inhibitors (BTKi) used for the treatment of some hematologic malignancies, like B cell lymphoma and chronic lymphocytic leukemia (CLL). This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.